TABLE 2.
Clinical characteristics and therapies of COVID‐19 confirmed psoriatic patients
| COVID‐19 positive quarantined at home (N = 17) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Age | Gender | PsA | PsO therapy | Hospitalization, days | COVID‐19 diagnosis | COVID‐19 therapy | Comorbidities | |
| 1 | 44 | F | _ | Ustekinumab 45 mg | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg every 8‐12 h × 10 days + azitromicin 500 mg/die × 7 days | _ |
| 2 | 40 | F | _ | Ustekinumab 90 mg | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg every 8‐12 h × 12 days | _ |
| 3 | 67 | M | _ | Ustekinumab 90 mg | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg every 8–12 h × 10 days + azitromicin 500 mg/die × 6 days | Hypertension, myocardial infarction |
| 4 | 68 | M | _ | Ustekinumab 90 mg | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg every 8–12 h × 10 days | Hypertension |
| 5 | 51 | M | _ | Ustekinumab 45 mg | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg twice/day × 10 days | _ |
| 6 | 63 | M | _ | Adalimumab biosimilar | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg twice/day × 10 days | Obesity and diabetes |
| 7 | 72 | M | X | Adalimumab biosimilar | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg twice/day × 10 days | Hypertension |
| 8 | 42 | F | X | Adalimumab | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg twice/day × 10 days | _ |
| 9 | 67 | M | _ | Etanercept biosimilar | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Amoxicillin 1000 mg twice per day × 7 days, paracetamol 1000 mg twice/day × 10 days | _ |
| 10 | 56 | M | _ | Etanercept biosimilar | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg twice/day × 10 days | _ |
| 11 | 43 | F | _ | Etanercept biosimilar | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg twice/day × 10 days | _ |
| 12 | 69 | M | _ | Secukinumab | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg twice/day × 10 days | _ |
| 13 | 37 | M | _ | Secukinumab | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg twice/day × 10 days | _ |
| 14 | 39 | M | _ | Ixekizumab | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg twice/day × 10 days | _ |
| 15 | 65 | M | _ | Ixekizumab | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg twice/day × 10 days + azitromicin 500 mg/die × 7 days | Hypertension, obesity |
| 16 | 66 | M | _ | Ixekizumab | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Paracetamol 1000 mg every 8 h × 10 days + azitromicin 500 mg/die × 7 days | Hypertension, stroke |
| 17 | 69 | M | _ | Guselkumab | 0 | Fever, anosmia, ageusia, astenia, cough, no hypoxia, no dyspnea | Amoxicillin 1000 mg twice per day × 7 days, paracetamol 1000 mg twice/day × 10 days | Hypertension, diabetes |
| COVID‐19 positive hospitalized (N = 5) | ||||||||
| 1 | 55 | F | X | Adalimumab (suspended) | 5 | Bilateral interstitial pneumonia | Lopinavir‐ritonavir 400 mg twice/day × 15 days + paracetamol 1000 mg every 8 h × 10 days | Diabetes, hypertension |
| 2 | 62 | M | _ | Ustekinumab 90 mg | 7 | Bilateral interstitial pneumonia | Oxigen × 2 days, lopinavir‐ritonavir 400 mg twice/day × 15 days, hydroxychloroquine 800 mg/die × 15 days, prednisone 25 mg per 8 days and 12.5 per 8 days | _ |
| 3 | 73 | M | _ | Ixekizumab | 7 | Bilateral interstitial pneumonia | Oxigen 1 day, amoxicillin 1000 mg twice per day × 7 days, hydroxychloroquine 800 mg/die × 10 days | _ |
| 4 | 74 | M | _ | Secukinumab | 5 | Bilateral interstitial pneumonia | Oxigen × 1 day, Amoxicillin 1000 mg twice per day× 7 days | Hypertension, transient ischemic attack |
| 5 | 48 | F | _ | Ustekinumab 90 mg | 8 | Bilateral interstitial pneumonia | Lopinavir‐ritonavir 400 mg twice/day × 10 days + paracetamol 1000 mg every 8 h × 10 days | |
[Correction added on 3 July, after first online publication: The N values in Table 2 have been corrected.]